Ability of Innate Defence Regulator Peptides IDR-1002, IDR-HH2 and IDR-1018 to Protect against Mycobacterium tuberculosis Infections in Animal Models

Tuberculosis is an ongoing threat to global health, especially with the emergence of multi drug-resistant (MDR) and extremely drug-resistant strains that are motivating the search for new treatment strategies. One potential strategy is immunotherapy using Innate Defence Regulator (IDR) peptides that...

Full description

Bibliographic Details
Main Authors:	Rivas-Santiago, Bruno, Castañeda-Delgado, Julio E., Rivas Santiago, Cesar E., Waldbrook, Matt, González-Curiel, Irma, León–Contreras, Juan C., Enciso-Moreno, Jose Antonio, del Villar, Victor, Mendez-Ramos, Jazmin, Hancock, Robert E. W., Hernandez-Pando, Rogelio
Format:	Online
Language:	English
Published:	Public Library of Science 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605426/

id	pubmed-3605426
recordtype	oai_dc
spelling	pubmed-36054262013-04-03 Ability of Innate Defence Regulator Peptides IDR-1002, IDR-HH2 and IDR-1018 to Protect against Mycobacterium tuberculosis Infections in Animal Models Rivas-Santiago, Bruno Castañeda-Delgado, Julio E. Rivas Santiago, Cesar E. Waldbrook, Matt González-Curiel, Irma León–Contreras, Juan C. Enciso-Moreno, Jose Antonio del Villar, Victor Mendez-Ramos, Jazmin Hancock, Robert E. W. Hernandez-Pando, Rogelio Research Article Tuberculosis is an ongoing threat to global health, especially with the emergence of multi drug-resistant (MDR) and extremely drug-resistant strains that are motivating the search for new treatment strategies. One potential strategy is immunotherapy using Innate Defence Regulator (IDR) peptides that selectively modulate innate immunity, enhancing chemokine induction and cell recruitment while suppressing potentially harmful inflammatory responses. IDR peptides possess only modest antimicrobial activity but have profound immunomodulatory functions that appear to be influential in resolving animal model infections. The IDR peptides HH2, 1018 and 1002 were tested for their activity against two M. tuberculosis strains, one drug-sensitive and the other MDR in both in vitro and in vivo models. All peptides showed no cytotoxic activity and only modest direct antimicrobial activity versus M. tuberculosis (MIC of 15–30 µg/ml). Nevertheless peptides HH2 and 1018 reduced bacillary loads in animal models with both the virulent drug susceptible H37Rv strain and an MDR isolate and, especially 1018 led to a considerable reduction in lung inflammation as revealed by decreased pneumonia. These results indicate that IDR peptides have potential as a novel immunotherapy against TB. Public Library of Science 2013-03-21 /pmc/articles/PMC3605426/ /pubmed/23555622 http://dx.doi.org/10.1371/journal.pone.0059119 Text en © 2013 Rivas-Santiago et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Rivas-Santiago, Bruno Castañeda-Delgado, Julio E. Rivas Santiago, Cesar E. Waldbrook, Matt González-Curiel, Irma León–Contreras, Juan C. Enciso-Moreno, Jose Antonio del Villar, Victor Mendez-Ramos, Jazmin Hancock, Robert E. W. Hernandez-Pando, Rogelio
spellingShingle	Rivas-Santiago, Bruno Castañeda-Delgado, Julio E. Rivas Santiago, Cesar E. Waldbrook, Matt González-Curiel, Irma León–Contreras, Juan C. Enciso-Moreno, Jose Antonio del Villar, Victor Mendez-Ramos, Jazmin Hancock, Robert E. W. Hernandez-Pando, Rogelio Ability of Innate Defence Regulator Peptides IDR-1002, IDR-HH2 and IDR-1018 to Protect against Mycobacterium tuberculosis Infections in Animal Models
author_facet	Rivas-Santiago, Bruno Castañeda-Delgado, Julio E. Rivas Santiago, Cesar E. Waldbrook, Matt González-Curiel, Irma León–Contreras, Juan C. Enciso-Moreno, Jose Antonio del Villar, Victor Mendez-Ramos, Jazmin Hancock, Robert E. W. Hernandez-Pando, Rogelio
author_sort	Rivas-Santiago, Bruno
title	Ability of Innate Defence Regulator Peptides IDR-1002, IDR-HH2 and IDR-1018 to Protect against Mycobacterium tuberculosis Infections in Animal Models
title_short	Ability of Innate Defence Regulator Peptides IDR-1002, IDR-HH2 and IDR-1018 to Protect against Mycobacterium tuberculosis Infections in Animal Models
title_full	Ability of Innate Defence Regulator Peptides IDR-1002, IDR-HH2 and IDR-1018 to Protect against Mycobacterium tuberculosis Infections in Animal Models
title_fullStr	Ability of Innate Defence Regulator Peptides IDR-1002, IDR-HH2 and IDR-1018 to Protect against Mycobacterium tuberculosis Infections in Animal Models
title_full_unstemmed	Ability of Innate Defence Regulator Peptides IDR-1002, IDR-HH2 and IDR-1018 to Protect against Mycobacterium tuberculosis Infections in Animal Models
title_sort	ability of innate defence regulator peptides idr-1002, idr-hh2 and idr-1018 to protect against mycobacterium tuberculosis infections in animal models
description	Tuberculosis is an ongoing threat to global health, especially with the emergence of multi drug-resistant (MDR) and extremely drug-resistant strains that are motivating the search for new treatment strategies. One potential strategy is immunotherapy using Innate Defence Regulator (IDR) peptides that selectively modulate innate immunity, enhancing chemokine induction and cell recruitment while suppressing potentially harmful inflammatory responses. IDR peptides possess only modest antimicrobial activity but have profound immunomodulatory functions that appear to be influential in resolving animal model infections. The IDR peptides HH2, 1018 and 1002 were tested for their activity against two M. tuberculosis strains, one drug-sensitive and the other MDR in both in vitro and in vivo models. All peptides showed no cytotoxic activity and only modest direct antimicrobial activity versus M. tuberculosis (MIC of 15–30 µg/ml). Nevertheless peptides HH2 and 1018 reduced bacillary loads in animal models with both the virulent drug susceptible H37Rv strain and an MDR isolate and, especially 1018 led to a considerable reduction in lung inflammation as revealed by decreased pneumonia. These results indicate that IDR peptides have potential as a novel immunotherapy against TB.
publisher	Public Library of Science
publishDate	2013
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605426/
_version_	1611964615666696192

Ability of Innate Defence Regulator Peptides IDR-1002, IDR-HH2 and IDR-1018 to Protect against Mycobacterium tuberculosis Infections in Animal Models

Similar Items